These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6881973)

  • 21. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent studies on antibiotics and small molecular immunomodulators with potential usefulness in treating lung cancer: Part II - Small molecular weight immunomodulators produced by microorganisms.
    Umezawa H
    Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):19-23. PubMed ID: 7056602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aminopeptidase inhibitor ubenimex (bestatin) inhibits the growth of human choriocarcinoma in nude mice through its direct cytostatic activity.
    Inoi K; Goto S; Nomura S; Isobe K; Nawa A; Okamoto T; Tomoda Y
    Anticancer Res; 1995; 15(5B):2081-7. PubMed ID: 8572606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combination chemotherapy with nedaplatin, bleomycin and ifosfamide for advanced cervical cancer of the uterus--a preliminary study for phase III clinical study].
    Noda K; Hirabayashi K; Terashima Y; Ozaki M; Yakushiji M; Hatae M; Kanazawa K
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1285-93. PubMed ID: 9279348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized controlled study of chemoimmunotherapy with bestatin of acute nonlymphocytic leukemia in adults.
    Ota K; Ogawa N
    Biomed Pharmacother; 1990; 44(2):93-101. PubMed ID: 2224060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bestatin treatment enhances the recovery of radiation induced impairments of the immunological reactivity of the blood lymphocyte population in bladder cancer patients.
    Blomgren H; Edsmyr F; von Stedingk LV; Wasserman J
    Biomed Pharmacother; 1986; 40(2):50-4. PubMed ID: 3756312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
    J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Secondary microbial metabolites with potentials for antineoplastic actions: antineoplastic antibiotics and immunopotentiators].
    Umezawa H
    Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1071-86. PubMed ID: 6191672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NTP Toxicology and Carcinogenesis Studies of Dimethyl Methylphosphonate (CAS No. 756-79-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1987 Nov; 323():1-172. PubMed ID: 12748730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
    Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
    Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule.
    Spiegel RJ; Blum RH; Levin M; Pinto CA; Wernz JC; Speyer JL; Hoffman KS; Muggia FM
    Cancer Res; 1982 Jan; 42(1):354-8. PubMed ID: 7053862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy with bestatin in inoperable lung cancer. A randomized trial.
    Takada M; Fukuoka M; Negoro S; Kusunoki Y; Matsui K; Masuda N; Sakai N; Ryu S; Takifuji N; Kudo S
    Acta Oncol; 1990; 29(6):821-5. PubMed ID: 2223156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule.
    Casper ES; Gralla RJ; Young CW
    Cancer Res; 1981 Jun; 41(6):2417-20. PubMed ID: 6940656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults.
    Ota K; Kurita S; Yamada K; Masaoka T; Uzuka Y; Ogawa N
    Cancer Immunol Immunother; 1986; 23(1):5-10. PubMed ID: 3533256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.
    Portielje JE; Kruit WH; Schuler M; Beck J; Lamers CH; Stoter G; Huber C; de Boer-Dennert M; Rakhit A; Bolhuis RL; Aulitzky WE
    Clin Cancer Res; 1999 Dec; 5(12):3983-9. PubMed ID: 10632329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased granulocyte phagocytosis after oral administration of bestatin, a new immunomodulator.
    Jarstrand C; Blomgren H
    J Clin Lab Immunol; 1982 Feb; 7(2):115-8. PubMed ID: 7069782
    [No Abstract]   [Full Text] [Related]  

  • 39. Screening of small molecular microbial products modulating immune responses and bestatin.
    Umezawa H
    Recent Results Cancer Res; 1980; 75():115-25. PubMed ID: 7232823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NTP Toxicology and Carcinogenesis Studies of Promethazine Hydrochloride (CAS No. 58-33-3) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Dec; 425():1-272. PubMed ID: 12616286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.